As of November 9, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Drugs Made In America Acquisition Corp. The largest reported stake is Karpus Management, Inc.'s, at 10.33%. 8 filings are on record since August 14, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Drugs Made In America Acquisition Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Karpus Management, Inc. · Sole voting: 2,507,817 · Shared voting: 0 · Sole dispositive: 2,507,817 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: First Trust Merger Arbitrage Fund · Sole voting: 675,366 · Shared voting: 0 · Sole dispositive: 675,366 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Mizuho Financial Group, Inc. · Sole voting: 2,058,605 · Shared voting: 0 · Sole dispositive: 2,058,605 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Glazer Capital, LLC · Sole voting: 0 · Shared voting: 999,899 · Sole dispositive: 0 · Shared dispositive: 999,899 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Feis Equities LLC · Sole voting: 1,232,775 · Shared voting: 0 · Sole dispositive: 1,232,775 · Shared dispositive: 0 · SCHEDULE 13G, 2026-06-26
Drugs Made In America Acquisition Corp. has 8 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of class a ordinary shares, par value $0.0001 per share ("ordinary shares"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Karpus Management, Inc. | 10.33% | 2,507,817 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Mizuho Financial Group, Inc. | 8.5% | 2,058,605 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Feis Equities LLC | 5.08% | 1,232,775 | SCHEDULE 13G, 2026-06-26 | 2026-06-18 |
| Hudson Bay Capital Management LP | 4.62% | 1,550,000 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| Glazer Capital, LLC | 4.12% | 999,899 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| First Trust Capital Management L.P. | 3.24% | 786,459 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Drugs Made In America Acquisition Corp. and the warning signs.
Free to see. No signup.
Keep reading
More on Drugs Made In America Acquisition Corp. and the records around it.
Companies that share a holder
- Hudson Bay Capital Management LP also filed stake reports on 34 other companies: Newbridge Acquisition Ltd (Nov 2026), Eos Energy Enterprises, Inc. (Nov 2026), FG Imperii Acquisition Corp. (Nov 2026)
- Feis Equities LLC also filed stake reports on 44 other companies: SPACCircle Acquisition Corp. (Oct 2026), Aperture AC (Oct 2026), Pine Tree Acquisition Corp. (Oct 2026)
- First Trust Merger Arbitrage Fund also filed stake reports on 47 other companies: TCW SPECIALTY LENDING LLC (Sep 2026), Blue Foundry Bancorp (Aug 2026), Centurion Acquisition Corp. (Aug 2026)
Watch Drugs Made In America Acquisition Corp.
Get an email when Drugs Made In America Acquisition Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Drugs Made In America Acquisition Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Drugs Made In America Acquisition Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Drugs Made In America Acquisition Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Karpus Management, Inc. | 2,507,817 | 0 | 2,507,817 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Mizuho Financial Group, Inc. | 2,058,605 | 0 | 2,058,605 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Feis Equities LLC | 1,232,775 | 0 | 1,232,775 | 0 | SCHEDULE 13G, 2026-06-26 |
| Lawrence M. Feis | 1,232,775 | 0 | 1,232,775 | 0 | SCHEDULE 13G, 2026-06-26 |
| Glazer Capital, LLC | 0 | 999,899 | 0 | 999,899 | SCHEDULE 13G/A, 2026-08-13 |
| Paul J. Glazer | 0 | 999,899 | 0 | 999,899 | SCHEDULE 13G/A, 2026-08-13 |
| First Trust Merger Arbitrage Fund | 675,366 | 0 | 675,366 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| First Trust Capital Management L.P. | 786,459 | 0 | 786,459 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| First Trust Capital Solutions L.P. | 786,459 | 0 | 786,459 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| FTCS Sub GP LLC | 786,459 | 0 | 786,459 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Drugs Made In America Acquisition Corp. by CUSIP G2847J104 and gives its principal executive office as 420 Lexington Avenue, Suite 1402, New York, NY 10170 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
5.08 - The percentage set forth in row 11 of the cover page for each Reporting Person is based on 24,276,913 Ordinary shares outstanding as of May 14,2026, as reported by the Issuer in its 10-Q filing for the period ending March 31, 2026, filed with the Securities and Exchange Commission on May 14,2026.Feis Equities LLC, SCHEDULE 13G, 2026-06-26
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Karpus Management, Inc. | 8.19% | SCHEDULE 13G/A |
| 2025-11-12 | Hudson Bay Capital Management LP | 4.62% | SCHEDULE 13G/A |
| 2026-05-14 | Mizuho Financial Group, Inc. | 6% | SCHEDULE 13G |
| 2026-06-26 | Feis Equities LLC | 5.08% | SCHEDULE 13G |
| 2026-08-13 | Glazer Capital, LLC | 4.12% | SCHEDULE 13G/A |
| 2026-08-13 | Mizuho Financial Group, Inc. | 8.5% | SCHEDULE 13G/A |
| 2026-08-14 | Karpus Management, Inc. | 10.33% | SCHEDULE 13G/A |
| 2026-08-14 | First Trust Capital Management L.P. | 3.24% | SCHEDULE 13G/A |
Questions about who owns Drugs Made In America Acquisition Corp.
Who owns Drugs Made In America Acquisition Corp.?
On this page, 3 holders' latest ownership filings report 5% or more of Drugs Made In America Acquisition Corp.: Karpus Management, Inc. (10.33%, Schedule 13G/A, filed 2026-08-14), Mizuho Financial Group, Inc. (8.5%, Schedule 13G/A, filed 2026-08-13) and Feis Equities LLC (5.08%, Schedule 13G, filed 2026-06-26).
Who are the largest shareholders of Drugs Made In America Acquisition Corp.?
By the share each holder's latest filing reports, the largest holders of Drugs Made In America Acquisition Corp. on this page are Karpus Management, Inc. (10.33%), Mizuho Financial Group, Inc. (8.5%) and Feis Equities LLC (5.08%).
When did Karpus Management, Inc. buy into Drugs Made In America Acquisition Corp.?
The filings give report dates, not purchase dates. The earliest filing from Karpus Management, Inc. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 8.19%; its latest, Schedule 13G/A filed 2026-08-14, reports 10.33%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Drugs Made In America Acquisition Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 29, 2025 | IPO filing, Form 424B4 | $10 a share | IPO filings | Source |
| January 6, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 9, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| November 25, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| November 7, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 27, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| September 6, 2024 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 1, 2024 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Drugs Made In America Acquisition Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.